[Secondary amyloidosis in patients with rheumatoid arthritis].
Yasuda
Masayuki
M
Center of Rheumatology, Beppu Medical Center, National Hospital Organization.
D000686:Amyloidosis / Q000175:diagnosis / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000150:complications*; D019643:Arthroplasty, Replacement; D003937:Diagnosis, Differential; D003956:Dialysis; D005938:Glucocorticoids / Q000627:therapeutic use; D017583:Hemodiafiltration; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D011379:Prognosis; D000685:Serum Amyloid A Protein / Q000378:metabolism; D000683:Serum Amyloid P-Component
D018501:Antirheumatic Agents; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D000685:Serum Amyloid A Protein; D000683:Serum Amyloid P-Component; D008727:Methotrexate